International Journal of Molecular Sciences Acceptance Rate 2026: How Selective Is IJMS?

Decision cue: If your molecular science paper is technically sound but wouldn't clear the Nature Communications bar, IJMS is a legitimate Q1 venue worth considering. Check scope match against recent issues before submitting.

Related: IJMS journal page • IJMS review time • Pre-submission checklist

The International Journal of Molecular Sciences acceptance rate sits around 30-40%, which puts it among the more accessible Q1 journals in molecular biology and biochemistry. Here's the full breakdown on selectivity, what typically gets rejected, and how the review process actually works.

The acceptance rate in context

IJMS accepts roughly 30-40% of submissions. The journal publishes about 5,000-6,000 papers per year across molecular biology, biochemistry, genetics, pharmacology, and related areas.

To put it in perspective:

• Nature Communications: ~20% acceptance
• PLOS ONE: ~40% acceptance
• IJMS: ~30-40% acceptance
• Scientific Reports: ~57% acceptance

IJMS is selective but not highly exclusive. A technically sound paper with a clear molecular science focus has a real chance. The journal does not require the broad significance that Science Advances or Nature Communications expect.

What IJMS publishes

IJMS covers molecular-level research across a wide range: biochemistry, molecular genetics, cell biology, structural biology, pharmacology, bioinformatics, and related disciplines. The scope is genuinely broad, which is both a strength (many papers fit) and a challenge (editors need to assess fit carefully).

The journal does not publish purely clinical research, epidemiology without molecular components, or engineering work without clear biological/molecular angle.

Desk rejection: what triggers it

Desk rejection at IJMS is less aggressive than at high-IF journals, but it does happen. Common reasons:

Out of scope. Clinical studies without molecular mechanistic work, purely computational papers without biological validation, or engineering papers without a clear molecular biology component get rejected before review.

Quality threshold failures. Papers with obvious methodological errors, missing controls, or conclusions unsupported by data are screened out. IJMS editors don't invest reviewers in papers that need fundamental redesign.

Language quality. MDPI journals have an explicit threshold for English quality. Papers where language problems impede scientific evaluation get desk rejected with a note recommending language editing before resubmission.

Redundancy. If your paper is clearly a replicate of published work without substantial new insight, it won't advance to review.

Desk decisions at IJMS typically arrive within 1-2 weeks.

The peer review process

IJMS uses external peer review with typically 2 reviewers. The journal runs a modified rapid review model: reviewers receive 7-14 day deadlines (with possible extensions) rather than the 3-6 week windows common at society journals.

What reviewers look for:

Methodological soundness comes first. Controls should be appropriate and clearly reported. Statistical analysis must match the data type and research question. IJMS reviewers are specialists in molecular sciences, so technical shortcuts get noticed.

Clarity of contribution matters. The paper should articulate what it adds to the existing literature. A well-executed but purely confirmatory study needs to explain why replication with a different model or system is valuable.

Data completeness. N numbers, biological replicates vs. technical replicates, and appropriate validation of key findings are standard review checkpoints.

Time to first decision

IJMS typically delivers first decisions in 15-30 days from submission. The rapid review model accelerates the process compared to traditional peer review timelines:

• Desk review: 5-14 days
• External peer review: 10-21 days
• Editorial decision after reviews received: 3-7 days

Total: typically 18-35 days to first decision for papers that pass desk review.

This is faster than most society journals and comparable to other MDPI journals. For authors with time pressure or those resubmitting after rejection elsewhere, this turnaround is a real practical advantage.

Decision outcomes

Acceptance after minor revision: Most common positive outcome. Reviewers request clarification, improved figures, or additional statistics. Authors typically have 5-10 days for minor revisions.

Major revision: Significant new experiments or reanalysis required. Less common than at journals with lower throughput but it does occur for papers close to the bar. IJMS gives 20-30 days for major revisions.

Rejection with option to resubmit: Substantial changes needed but the topic fits. Treated as a new submission.

Rejection: Outside scope, quality threshold not met, or irretrievably flawed methodology.

How selective is IJMS really?

The 30-40% acceptance rate reflects a journal that has clear standards but isn't hunting for field-changing results. If your paper:

• Is within molecular sciences scope
• Has adequate controls and sound methodology
• Makes a clear if modest contribution to the literature
• Is written clearly enough for reviewers to evaluate

...then IJMS is a realistic target. The journal is more accessible than high-IF journals but more demanding than bottom-tier open access journals.

APC: what you pay

IJMS charges an Article Processing Charge (APC) of CHF 2,700 (approximately USD 3,000-3,200). This applies to research articles. Many institutions and funders cover MDPI APCs through read-and-publish agreements or OA funds.

Alternatives if IJMS feels borderline

If your paper might be too marginal for IJMS or you need a broader search:

• Biomolecules (MDPI, IF 4.9) - similar tier, narrower focus on biomolecular structure and function
• Cells (MDPI, IF 5.1) - cell biology focus
• Molecules (MDPI, IF 4.2) - chemistry-forward molecular science
• Journal of Molecular Biology (Elsevier, IF 5.6) - more selective, higher prestige for structural and molecular biology
• PLOS ONE (IF 3.2) - broad scope, lower bar for novelty, higher acceptance rate

What to check before submitting

The most common reason a solid IJMS-level paper gets desk rejected: scope mismatch. Read the aims and scope carefully. Check that your study involves molecular-level investigation - not just clinical outcomes or bulk tissue experiments without mechanistic insight.

If you're uncertain whether your paper is ready, a Pre-Submission Diagnostic evaluates your manuscript against the journal's specific criteria and flags what reviewers would likely flag.

The bottom line

IJMS acceptance rate of ~30-40% makes it genuinely accessible for molecular science research that doesn't clear the high-impact journal bar. The rapid review timeline (15-30 days to first decision) adds practical appeal. The main risk is scope mismatch - review the aims carefully before submitting.

Sources

• MDPI editorial policies and IJMS author guidelines (March 2026)
• Clarivate Analytics, Journal Citation Reports 2024 (JIF 4.9, Q1)
• Author experience data from SciRev and academic forums
• IJMS journal overview
• IJMS review time 2026